Navigation Links
Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference
Date:10/18/2010

DURHAM, N.C., Oct. 18 /PRNewswire/ -- Argos Therapeutics today announced that Jeff Abbey, the company's president and chief executive officer, will present an overview of its Arcelis™ dendritic cell-based immunotherapy at 3:30 p.m. EDT on Oct. 21 at the inaugural Cancer Immunotherapy Conference in New York.

In addition, Charles Nicolette, Ph.D., the company's chief scientific officer and vice president of research and development, will participate in a panel discussion titled "Autologous versus allogeneic immunotherapy" at 2:45 p.m. EDT that day. The conference will take place at the New York Academy of Medicine. A live Webcast of the conference can be accessed by visiting www.mdbpartners.com/vaccine.

About the Arcelis™ Technology

Arcelis is Argos' proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies for cancer, HIV and other infectious diseases. This platform is based on optimizing a patient's own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune response. To address the challenge of the unique genetic profile of each patient's disease and the genetic mutations of that disease, Argos loads the autologous dendritic cells with a sample of messenger RNA ("mRNA") isolated from the patient's disease. Through this process, dendritic cells can potentially prime immune responses to the entire antigenic repertoire, resulting in an immunotherapeutic that is customized to the patient's specific disease.

About Argos Therapeutics, Inc.Argos is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases and transplantation rejection. The Company has generated multiple platform technologies and a diverse pipeline of products based on its expertise in the biology of dendritic cells — the master switch that turns the immune system on or off. www.argostherapeutics.com Contacts:David Schull or Andreas MarathovouniotisRusso Partners LLC(212) 845-4271 or (212) 845-4235david.schull@russopartnersllc.com or andreas.marathis@russopartnersllc.comJeff AbbeyArgos Therapeutics(919) 287-6308jabbey@argostherapeutics.com
'/>"/>

SOURCE Argos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Argos Therapeutics to Present Recent Clinical Developments and Corporate Overview at 18th Annual BioPartnering Europe
2. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
3. Talecris Biotherapeutics Receives FDA Approval for Gamunex®-C
4. Prime Therapeutics Announces URAC Accreditation
5. Halozyme Therapeutics Announces Implementation of Development Focused Strategy
6. Talecris Biotherapeutics to Report Third Quarter 2010 Financial Results
7. Michael R. Bristow, M.D. Ph.D. Joins Nile Therapeutics Scientific Advisory Board
8. Halozyme Therapeutics to Host Analyst Meeting on October 14 in New York
9. Prime Therapeutics Hires Peter Wickersham, Senior Vice President Cost of Care
10. Osseon® Therapeutics Introduces New Osseoflex® DR Steerable Bone Drill
11. Weikang Bio-Technology Plans to Launch New Therapeutics in First Quarter 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Conference Call and Webcast to Follow Vanda Pharmaceuticals Inc. ... results for the fourth quarter of 2016 on Wednesday, February 15, ... ... PM ET on Wednesday, February 15, 2017, during which management will ... other corporate activities. To participate in the conference call, please dial ...
(Date:1/19/2017)... , Jan. 19, 2017  Stealth BioTherapeutics Inc. ( ... treat mitochondrial dysfunction, today announced new additions to its ... as Chief Medical Officer, and Daniel Geffken ... that Jim Carr , Pharm.D. has been promoted ... are pleased to welcome Doug and Daniel to our ...
(Date:1/19/2017)... 2017  Abaxis, Inc. (NasdaqGS: ABAX ), ... and consumables for the medical and veterinary markets worldwide, ... results for the third quarter fiscal year 2017, ended ... p.m. ET on Thursday, January 26, 2017.  The Company ... year 2017 after the market closes on Thursday, January ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... 2017 , ... “Mary Magdalene: Grace is Greater than Sin”: a unique ... Jesus Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the creation of ... interacting with countless women who had little knowledge of the female characters portrayed in ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... Oscillating Positive Expiratory Pressure (OPEP) device, was featured in a study indicating superior ... MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive Expiratory Pressure Devices During ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Land of More and More”: ... of world hunger, and shares the simple and achievable answer. “The Land of More ... of the Fairview Missionary Church in Angola, Indiana where he works with the children’s ...
(Date:1/19/2017)... ... 19, 2017 , ... Next week after January 20th, the fear for many ... that circumvent health needs of over 30 million. Many interviews with Dr. Carol Francis ... government public servants were suppose to prioritize. Interviews provided below. , Among ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... and scientists from around the world, announces the launch of its newly redesigned ... easy portal to research breakthroughs and trending news, vital information on upcoming virtual ...
Breaking Medicine News(10 mins):